Collegium Pharmaceutical (COLL) Projected to Announce Quarterly Earnings on Thursday

Collegium Pharmaceutical (NASDAQ:COLL) will likely be issuing its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to announce earnings of $1.86 per share and revenue of $216.03 million for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:00 AM ET.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings data on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. The firm had revenue of $199.88 million during the quarter, compared to analysts’ expectations of $199.62 million. Collegium Pharmaceutical had a net margin of 5.93% and a return on equity of 91.43%. The business’s revenue for the quarter was up 6.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.68 earnings per share. On average, analysts expect Collegium Pharmaceutical to post $6.42 EPS for the current fiscal year and $5.89 EPS for the next fiscal year.

Collegium Pharmaceutical Stock Performance

COLL stock opened at $23.73 on Wednesday. The firm has a market cap of $772.65 million, a PE ratio of 3.39, a P/E/G ratio of 0.74 and a beta of 0.75. The company has a current ratio of 1.03, a quick ratio of 0.84 and a debt-to-equity ratio of 3.32. The business’s 50-day moving average price is $23.16 and its two-hundred day moving average price is $33.13. Collegium Pharmaceutical has a 1-year low of $21.43 and a 1-year high of $50.79.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. Oppenheimer started coverage on shares of Collegium Pharmaceutical in a report on Wednesday, September 23rd. They set an “outperform” rating and a $50.00 target price on the stock. Truist Financial started coverage on shares of Collegium Pharmaceutical in a research report on Wednesday, September 9th. They issued a “buy” rating and a $49.00 price objective on the stock. Needham & Company LLC reduced their target price on shares of Collegium Pharmaceutical from $56.00 to $46.00 and set a “buy” rating for the company in a report on Thursday, August 6th. Weiss Ratings downgraded shares of Collegium Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, September 4th. Finally, Leerink Partners started coverage on Collegium Pharmaceutical in a research report on Wednesday, September 9th. They issued an “outperform” rating and a $45.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $48.71.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on developing and commercializing medicines for pain management and central nervous system disorders. The company primarily serves the U.S. market and emphasizes products designed to address significant patient and healthcare-provider needs.

Its pain portfolio includes Xtampza ER, an extended-release oxycodone formulation designed with abuse-deterrent properties, as well as Nucynta and Nucynta ER, which contain tapentadol and are used to treat acute and chronic pain.